This research document defines 'disease stability' as a new therapeutic indicator for chronic obstructive pulmonary disease (COPD) and verifies its clinical significance. Stability is presented as an ...
10don MSN
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales ...
Advancements in COPD treatment are offering relief to thousands of Kentuckians by targeting inflammation directly without the ...
Background Pulmonary rehabilitation (PR) is the cornerstone of non-pharmacological treatment for chronic obstructive ...
Persistent access barriers leave many treatment candidates without advanced therapy as physicians look for stronger disease ...
Precision medicine approaches for chronic obstructive pulmonary disease (COPD) are lagging, creating gaps in care and leaving ...
An experimental drug is offering new hope for the millions of Americans living with COPD. In late-stage clinical trials, an antibody treatment called Tozorakimab reduced scary, damaging lung ...
AstraZeneca’s experimental COPD drug has significantly reduced flare-ups in two late-stage trials, making FDA approval in ...
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) suggests escalating treatment in patients with chronic ...
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) ...
Congress 2026, AstraZeneca presented the design of the Phase IIb PRESTO trial, a large study set to evaluate whether AZD6793, ...
Researchers conducted a cohort study to compare lung cancer risk among patients with COPD and T2DM using SGLT2 inhibitors vs sulfonylureas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results